Maryam Dehghankhalili - Student Research Committee, Department of Surgery, Shiraz University of Medical Sciences
Vahid Zangouri - Breast Diseases Research Center, Shiraz University of Medical Sciences
Abtin Vahidi - Student Research Committee, Department of Surgery, Shiraz University of Medical Sciences
Majid Akrami - Student Research Committee, Department of Surgery, Shiraz University of Medical Sciences

BACKGROUND: The combination of cytoreductive surgery and preoperative adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) have been demonstrated to be associated with improved the outcome of patients with intraperitoneal malignancies especially the gynecologic cancers. The aim of the current review is to provide a comprehensive overview of the indications, techniques and complications of HIPEC in a variety of intraperitoneal malignancies. METHODS: This is a systematic review of the current literature published on the issue. We search the electronic databases including Medline, Scopus, CINAHEL, Embase and Scholar using the appropriate keywords. All the appropriate article between 2000 and 2018 were retrieved and evaluated for eligibility. The data were extracted and assessed using a database. The results were provided to cover the issues completely. RESULTS: We overall Several methods of delivering hyperthermic intraperitoneal chemotherapy (HIPEC) have been described, but no significant differences in treatment outcomes, morbidity, or safety have been found among them, and the ultimate choice between them is left to individual preference or institutional criteria. These methods include the open, closed and mixed methods. Administration of HIPEC is safe for the personnel working in the operating room; chemotherapy exposure during the procedure is negligible provided universal precautions, individual protection measures, and environmental safety guidelines are followed. Proper education of operating room staff about the essentials of HIPEC and proper chemotherapy handling is the first safety requirement. CONCLUSION: HIPEP is a considered a safe treatment option for patients with intraperitoneal malignancies especially the ovarian cancer being associated with increased gross total resection, decreased mortality and increased survival when followed by cytoreduction surgery. the knowledge of the current advancements is required for an oncologic surgeon.

Hyperthermia; Safety; Intraperitoneal chemotherapy; Technique; Peritoneal neoplasms; Complications